Zacks Investment Research lowered shares of Aileron Therapeutics (NASDAQ:ALRN) from a buy rating to a hold rating in a research report sent to investors on Wednesday.
According to Zacks, “Aileron Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engages in developing and commercializing a novel class of therapeutics primarily in the United States. The companys lead product includes ALRN-6924, targets the tumor suppressor protein p53 for the treatment of a range of cancers which are in clinical stage. Aileron Therapeutics, Inc. is based in Cambridge, Massachusetts. “
Separately, ValuEngine upgraded shares of Aileron Therapeutics from a hold rating to a buy rating in a research note on Thursday, November 1st.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ALRN. Renaissance Technologies LLC acquired a new position in Aileron Therapeutics in the third quarter valued at $137,000. Parkwood LLC acquired a new position in Aileron Therapeutics in the third quarter valued at $149,000. Vanguard Group Inc boosted its stake in Aileron Therapeutics by 8.0% in the third quarter. Vanguard Group Inc now owns 96,415 shares of the company’s stock valued at $265,000 after acquiring an additional 7,109 shares in the last quarter. Bridgeway Capital Management Inc. boosted its stake in Aileron Therapeutics by 78.6% in the third quarter. Bridgeway Capital Management Inc. now owns 113,600 shares of the company’s stock valued at $312,000 after acquiring an additional 50,000 shares in the last quarter. Finally, Millennium Management LLC boosted its stake in Aileron Therapeutics by 565.4% in the second quarter. Millennium Management LLC now owns 123,658 shares of the company’s stock valued at $670,000 after acquiring an additional 105,073 shares in the last quarter. Institutional investors own 9.08% of the company’s stock.
About Aileron Therapeutics
Aileron Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of therapeutics in the United States. The company's lead product candidate is ALRN-6924, a stapled peptide, which is in Phase I clinical trial for the treatment of advanced solid tumors or lymphomas; Phase IIa clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and Phase IIb trial to treat AML/MDS in combination with cytosine arabinoside.
Read More: What is the return on assets formula?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aileron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.